A vaccine It slows the progression of one of the deadliest cancer Can be manufactured In bulk, researchers say.
The test has hoped patients after a test The existence of more than half the participants increased Pancreas,
Researchers described the findings as “remarkable” and already started testing the efficiency of JAB between a large group. Pancreatic and intestinal cancer patients,
JAB uses a new type of immunotherapy. It is designed to improve vaccine delivery for lymph nodes, which act as filters for foreign substances in the body, including cancer cells and infections.
Pancreatic and intestinal cancer often make a mutation in a gene called KRAS, which plays an important role in the development of tumors, and scientists developed jab to recognize KAB and attack the cross-motent cancer cells.
Study, which is published in the magazine Nature therapyJAB on 20 patients with pancreatic cancer and five patients with bowel cancer.
When participants were followed after 20 months, 68 percent developed specific immune reactions to mutant cross tumor proteins.
Participants who had the strongest immune response lived for a long time and remained cancer-free longer than people with weak reactions.
Researchers found that the patient survived about two years and five months after receiving the vaccine.
In comparison, three out of three of the 10 people suffering from pancreatic cancer survive for a year.
The poorest survival rate is due to late detection in pancreatic cancer. This usually does not cause symptoms in the early stages, and as it increases, it can cause abdominal pain, yellow, unexplained weight loss of the skin, and changes in stools.
Once they receive a diagnosis, many patients see their cancer returning even after treatment such as radiotherapy and chemotherapy.
But the test showed that JAB can help prevent cancer from returning to more than 15 months.
Unlike other cancer jabs, who are individual to individual patients, it is a vaccine, ELI-002 2p, a single version that can be given to all patients.
This “off-the-shelf” version means that it can be manufactured in bulk and can be given more rapidly.
Dr. Dani Edmonds, Research Information Manager Cancer Research UKSaid: “Although we have helped double the existence of cancer in the UK in the last 50 years, progress has not been the same for pancreatic cancer, which is difficult to treat.
“Therefore, it is promised to see that vaccines can help people with pancreatic and bowel cancer to free cancer for long.
“Results suggest that vaccine may promote immune system against cancer in some people after standard treatment.
“These people survived and remained free from disease for longer than those who did not strengthen an immunity after vaccination.
“Large controlled tests are required to confirm these initial conclusions about the benefits of the vaccine.
“More research needs to understand why some people benefit from the vaccine while others do not, so we can ensure that we are beating cancer for all.”
However, Professor Richard Sulivan, director of the Center for Conflict and Health Research at King’s College London, suggested that the study does not prove that the vaccine is ready for use.
“There is some interesting science in this study, but it is a long way to prove any type of clinical utility,” he said.
“They mix colorectal cancer with pancreatic cancer-two widely different cancer diagnoses very different diseases, even though the latter is surgery saved. East is also diagnosed with very good disease with late stage disease, while the latter is also bad, even though early degeneration, and saved.”
